Biopharmaceutical investors like blockbuster drugs. And so far in 2019, there have been several new drugs to enter the market that hold the potential to generate $1 billion or more in annual sales over the next few years.
Market researcher EvaluatePharma recently issued its half-year report that ranked the biggest new drugs approved by the U.S. Food and Drug Administration (FDA) year to date. AbbVie (NYSE: ABBV), Johnson & Johnson (NYSE: JNJ), Novartis (NYSE: NVS), and Pfizer (NYSE: PFE) each claimed at least one drug on the list. Here are the five biggest new drugs approved in 2019 so far.